drugset / Trial / NCT03328234

Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

NCT03328234

Phase 3 Unknown 2 enrolled Chinese Academy of Medical Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

The investigators aimed to compare elective nodal irradiation versus involved field irradiation with or without concurrent chemotherapy and the addition of consolidation chemotherapy for patients with extensive lymphatic metastasis of esophageal cancer.

Timeline

Start
2017-09-01
Primary completion
2021-08-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 20 mg/m2
Subject Cisplatin Other / unclassified 25 mg/m2
Subject Cisplatin Other / unclassified 50 mg/m2
Subject Cisplatin Other / unclassified 80 mg/m2
Subject Lobaplatin Small molecule 20 mg/m2
Subject Lobaplatin Small molecule 25 mg/m2
Subject Lobaplatin Small molecule 50 mg
Subject Nedaplatin Small molecule 20 mg/m2
Subject Nedaplatin Small molecule 25 mg/m2
Subject Nedaplatin Small molecule 50 mg/m2
Subject Nedaplatin Small molecule 80 mg/m2
Subject Paclitaxel Small molecule 45 mg/m2
Subject Paclitaxel Small molecule 50 mg/m2
Subject Paclitaxel Small molecule 135 mg/m2
Subject Paclitaxel Small molecule 150 mg/m2

Indications

No indication recorded.